Form 4: Guardant Health Director Sells Shares Under 10b5-1 Plan

Guardant Health Director Meghan V. Joyce sold 100 shares of common stock for $65.84 per share, executed under a pre-arranged Rule 10b5-1 plan.

Summary

• Meghan V. Joyce, a Director at Guardant Health, Inc. (GH), disposed of 100 shares of common stock.
• The transaction occurred on September 2, 2025, at a price of $65.84 per share.
• The sale was executed pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Ms. Joyce beneficially owns 11,183 shares of Guardant Health common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, the small volume (100 shares) and the execution under a Rule 10b5-1 plan mitigate any strong negative interpretation, suggesting a pre-planned financial management action rather than a reaction to new company-specific news.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not a reaction to recent non-public information.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived as a neutral to slightly negative signal by investors.

Risks

• While not explicitly a risk, insider selling, even if pre-scheduled, can sometimes be interpreted by the market as a signal of management's outlook, potentially influencing investor sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

Insider transactions, particularly by directors, are routinely monitored by investors for insights into management's perspective on the company's valuation and future prospects. Transactions under Rule 10b5-1 plans are common for executives to manage personal finances while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders may note the director's sale, but given the small volume and 10b5-1 plan, it is unlikely to significantly alter their investment thesis.

Key Dates

Recommendation

The sale of 100 shares by a director, executed under a pre-arranged 10b5-1 plan, is a routine event and represents a very small fraction of the director's total holdings. This transaction alone does not provide sufficient new information to warrant a change in investment recommendation for Guardant Health, Inc. Investors should continue to evaluate the company based on its fundamental performance and broader market conditions.

Keywords

Guardant Health, GH, insider trading, Form 4, stock sale, director, Meghan V. Joyce, 10b5-1 plan